GLP-2 (HUMAN)

Base Information

• Chemical Name: GLP-2 (HUMAN)
• CAS No.: 223460-79-5
• Molecular Formula: C165H254 N44 O55 S
• Molecular Weight: 3766.10906
• Mol file: 223460-79-5.mol

Synonyms:1: PN:US6297214 SEQID: 1 claimed protein; 1: PN: WO2004035624 FIGURE: 1 claimedprotein; 26: PN: WO2009099763 SEQID: 663 claimed protein; 2: PN: US6184201SEQID: 2 unclaimed protein; 2: PN: WO2005019262 SEQID: 2 claimed protein; 6:PN: WO2005019262 SEQID: 2 claimed protein; Glucagon-like peptide II (human);Human glucagon-like peptide-2

Chemical Property of GLP-2 (HUMAN)

Chemical Property:

• PSA: 0.00000
• LogP: 0.00000
• Storage Temp.: −20°C

Purity/Quality:

99% ^*data from raw suppliers

Glucagon Like Peptide 2 ^*data from reagent suppliers

Safty Information:

• Safety Statements: 22-24/25

MSDS Files:

Useful:

• Biological functions: Compared with GLP-1 and glucagon receptors, GLP-2 receptor expression is more restricted, occurring predominantly in the gastrointestinal tract, brain, and lung. In the rat, the GLP-2 receptor is most abundant in the jejunum, followed by the duodenum, ileum, colon, and stomach, and at very low levels in several other tissues including the central nervous system. The gastrointestinal tract, from the stomach to the colon, is the principal target for GLP-2 action. It has been suggested that GLP-2 may exert diverse actions involved mainly in the control of gastrointestinal growth and function (for example, epithelial integrity, motility, and secretion; local blood flow; and nutrient uptake and utilization). A stimulatory effect of GLP-2 on glucagon secretion from the human pancreas has also been reported. However, the GLP-2 receptor is not localized to the known target cells of GLP-2 tropic action, but to scattered enteroendocrine cells, enteric neurons, and subepithelial myofibroblasts. These results suggest that paracrine and/or neural pathways may mediate the intestinal tropic actions of GLP-2. It has been reported that GLP-2 acts through a neural pathway to affect intestinal crypt cell c-fos expression, and through a nitric oxide-dependent mechanism to affect intestinal blood flow. For GLP-2-induced epithelial growth, KGF and IGF-1, secreted from subepithelial myofibroblasts, act as essential mediators in response to GLP-2. GLP-2 receptor mRNA expression has also been found in the normal human cervix, but its functional relevance is not yet known. The GLP-2 receptor is also expressed in?the central nervous system including the hypothalamus. Central GLP-2 is expected to be related to the regulation of feeding behavior. Several studies suggest that GLP2 exerts beneficial effects on glucose metabolism, especially in conditions related to the increased uptake of energy, such as obesity, at least in the animal model.
• Description: GLP-2 is cosecreted with GLP-1 in response to nutrient ingestion. The principal role of GLP-2 appears to be the maintenance of the growth and absorptive function of the intestinal mucosal villus epithelium. GLP-2 was first identified as a novel peptide following the cloning of the proglucagon gene in the early 1980s, and subsequently the biosynthesis and release of GLP-2 were confirmed by isolation and characterization from the porcine and human small intestine. The biological role of GLP-2 as a stimulator of intestinal epithelial proliferation was first demonstrated in 1996.
• Clinical Use: The pharmacological application of GLP-2 has been recognized and assessed in preclinical and clinical investigations to prevent or treat a number of intestinal diseases, including short bowel syndrome, Crohn’s disease, inflammatory bowel disease, chemotherapyinduced intestinal mucositis, colon carcinogenesis, and small bowel enteritis. The US Food and Drug Administration has accepted Teduglutide, an analog of GLP-2, for use in adult patients with short bowel syndrome.